PharmaLytica 2021 Hyderabad review.

Pfizer to stop manufacturing operations in Chennai, Aurangabad units

 

 

Over 1,700 employees working in these two factories are expected to be impacted by the decision. While the company is shutting down the two facilities, plans are afoot to expand the Vizag manufacturing facility, which also came as part of the acquisition.

Pfizer said that it conducted a thorough evaluation of the Irungattukottai and Aurangabad sites and concluded that due to a significant fall in product demand, manufacturing at these sites is not viable. “As a result, Pfizer is announcing that both the Aurangabad and Irungattukottai sites will immediately cease manufacturing with the intention to exit both sites as soon as possible in 2019. The exact timing of the exit of the sites is to be determined,”

The Irungattukottai facility was producing beta-lactam antibiotics while the Aurangabad facility was manufacturing penicillin and penem API during the period. It was coming up with a green field expansion plant in Vizag for speciality injectables then.

The Chennai facility has received several observations from the US Food and Drug Administration (US FDA) in the past, the latest being in July 2018. This was because it was not following quality control norms and lacks data related to laboratory records.

The facility had earlier received observations from the US FDA as part of inspections in 2013 and 2015, according to reports.

The Irungattukottai and Aurangabad sites are purely export-oriented and do not supply products for Pfizer’s India commercial operations

 

 











https://www.business-standard.com/

×

This Website Uses Cookies for Google Analytics, to improve your experience and to show you personalized advertising. By using this website you agree to our COOKIES AND PRIVACY POLICY...Learn More